Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1990-6-14
|
| pubmed:abstractText |
Twenty-four patients with 26 apudomas have been treated with Sandostatin (octreotide) in Belfast. The 2 patients with vipoma showed an excellent response clinically and biochemically. Of 15 patients with carcinoids, Sandostatin improved the diarrhoea in 70%, flush in 58%, and wheeze in 100% of patients. Patients with insulinoma and the Zollinger-Ellison syndrome were unresponsive to Sandostatin. In general, the response to Sandostatin appeared to decline as the tumour size increased and tumour markers rose. Side effects have not been a problem.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0012-2823
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
45 Suppl 1
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
11-4; discussion 15-6
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:2159429-Apudoma,
pubmed-meshheading:2159429-Carcinoid Tumor,
pubmed-meshheading:2159429-Diarrhea,
pubmed-meshheading:2159429-Female,
pubmed-meshheading:2159429-Flushing,
pubmed-meshheading:2159429-Gastrinoma,
pubmed-meshheading:2159429-Humans,
pubmed-meshheading:2159429-Insulinoma,
pubmed-meshheading:2159429-Northern Ireland,
pubmed-meshheading:2159429-Octreotide,
pubmed-meshheading:2159429-Respiratory Sounds,
pubmed-meshheading:2159429-Vipoma,
pubmed-meshheading:2159429-Zollinger-Ellison Syndrome
|
| pubmed:year |
1990
|
| pubmed:articleTitle |
Sandostatin and the Belfast experience.
|
| pubmed:affiliation |
Institute of Clinical Science, Queen's University, Belfast, UK.
|
| pubmed:publicationType |
Journal Article
|